Complete tumor rejection was greatest in metastatic HER2+BC (NDL, immune-excluded TME with low TMB) when one week of aPD-1 priming was added to the HT + CpG + Dox protocol, which provoked systemic adaptive immunity. The gene discussed is ERBB2; the disease is breast cancer.